COGENT BIOSCIENCES INC (COGT)

What COGENT BIOSCIENCES INC does

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for oncology and other serious diseases. The company's lead program is bezuclastinib, a tyrosine kinase inhibitor in clinical development. Cogent relies on third-party contract organizations to conduct clinical trials, manufacture its product candidates, and supply active pharmaceutical ingredients. The company is unprofitable and has incurred net losses since inception, funding operations through equity offerings and debt financing.

Fundamentals

• Price$40.51 as of 2026-07-09 close
• Market cap$6.9B as of 2026-07-10
• 1-year return+308.7% as of 2026-07-09 close
• Net margin-264.1% as of 2026-07-10
• ROE-83.3% as of 2026-07-10
• Debt / equity0.37 as of 2026-07-10
• Beta0.33 as of 2026-07-10

Ask why COGT looks like this →

Key risks (from latest filing)

["Bezuclastinib program failure risk: Business is highly dependent on the success of bezuclastinib; failure to develop this candidate or expand the pipeline would severely impact the company","Regulatory and clinical trial risk: Interim and preliminary trial data may change as more patient data becomes available; FDA may disagree with regulatory plans; unacceptable side effects could force abandonment of development","Funding and profitability risk: Company has incurred net losses since inception and anticipates continued losses; requires additional capital to complete development and commercialization; indebtedness could limit cash flow available for operations"]

See COGT's biggest risks from its latest 10-Q →

Competitors & peers

• Gritstone bio
• Blueprint Medicines
• Exelixis
• Adaptimmune Therapeutics

Not quite? Describe exactly what you want →